Madison Scientific Inc.
Develops smart neuro devices to rework hydrocephalus management.
Website: https://madisonscientific.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Madison Scientific Inc. (operating as MadSci) |
| Tagline | Smart neuro devices for hydrocephalus management |
| Headquarters | Chicago, IL, United States |
| Founded | 2020 |
| Stage | Seed |
| Business Model | Hardware + Software (implantable device with connected monitoring) |
| Industry | Healthtech / Medical Devices |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | ~$10,000,000 [Neuro News International] [Crunchbase, September 2025] |
Links
PUBLIC
- LinkedIn: https://www.linkedin.com/company/madison-scientific-inc
- Crunchbase: https://www.crunchbase.com/organization/madison-scientific
- PitchBook: https://pitchbook.com/profiles/company/466913-44
- Catalytic Impact Foundation portfolio page: https://www.cifimpact.org/madsci
- Impact Foundation portfolio page: https://www.impactfoundation.org/portfolio/madisonscientific
Executive Summary
PUBLIC
Madison Scientific, which markets itself as MadSci, is a Chicago-based medical device startup building an implantable shunt system intended to modernize the standard of care for hydrocephalus, a neurological condition treated today with devices whose core architecture has changed little in decades. The company was founded in 2020 by Tyler Wanke, a physician-entrepreneur whose prior ventures include Innoblative Designs and EDGe Surgical [Northwestern University Farley Center]. Its lead product, referred to publicly as SmartShunt, pairs an adjustable valve with real-time intracranial pressure (ICP) monitoring, a combination intended to give neurosurgeons longitudinal data that conventional shunts do not produce [Hydrocephalus Association] [The Org]. In 2025, the company closed approximately $10 million in seed capital across two tranches: a $7 million round in March led by WARF Ventures, and a $3 million extension in September [Crunchbase, March 2025] [Crunchbase, September 2025]. The cap table also includes Isthmus Project alongside mission-aligned backers Impact Foundation and Catalytic Impact Foundation [Catalytic Impact Foundation] [Isthmus Project]. The hydrocephalus shunt category is small but durable: third-party estimates place the global market between roughly $296 million and $526 million in 2024-2025, with low-single-digit CAGRs [Global Market Insights] [Mordor Intelligence]. Over the next 12-18 months, watch for regulatory milestones, the shape of any first-in-human or pilot clinical work, and whether MadSci builds out a clinical and commercial leadership bench around its solo founder.
Data Accuracy: GREEN -- Confirmed by Crunchbase, Neuro News International, MobiHealthNews and Catalytic Impact Foundation.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed (closed two tranches in 2025) |
| Business Model | Implantable hardware paired with monitoring software |
| Industry / Vertical | Neurosurgical medical devices, hydrocephalus management |
| Technology Type | Biotech / Life Sciences, connected implantable |
| Geography | United States (Chicago, IL HQ) |
| Growth Profile | Venture scale, regulated medical device path |
| Founding Team | Solo founder (Tyler Wanke) |
| Funding | ~$10M seed disclosed across March and September 2025 |
Company Overview
PUBLIC
Madison Scientific was incorporated in 2020 and operates out of Chicago, with research and clinical ties to the Midwest medical-device ecosystem [PitchBook] [Crunchbase]. The company's public identity is dual: the legal name Madison Scientific Inc. appears on funding and database filings, while press coverage and the SmartShunt product narrative use the shorter MadSci brand [Neuro News International] [BioSpace]. Founder and CEO Tyler Wanke has framed the company around a single clinical problem: the high failure and revision rate of cerebrospinal fluid shunts, which today are typically implanted without continuous feedback on whether they are functioning as intended [Isthmus Project].
The most consequential milestones to date are financial and institutional rather than clinical. In March 2025, MadSci closed a $7 million seed round led by WARF Ventures, the venture arm associated with the Wisconsin Alumni Research Foundation, in a financing covered by both BioSpace and the Chicago Business Journal [BioSpace] [Chicago Business Journal]. A second seed tranche of $3 million followed in September 2025, bringing total disclosed seed capital to approximately $10 million [Crunchbase, September 2025] [Neuro News International]. The company has also been recognized in the portfolios of Impact Foundation and Catalytic Impact Foundation, two donor-advised philanthropic vehicles that back mission-driven medical innovation [Impact Foundation] [Catalytic Impact Foundation].
Clinical, regulatory and commercial milestones (such as FDA submissions, IDE approvals, first-in-human implants, or pilot site agreements) have not been publicly disclosed at the time of writing. Investors evaluating MadSci should treat the company as pre-clinical-readout and pre-revenue based on what is currently in the public record.
Data Accuracy: GREEN -- Confirmed by Crunchbase, BioSpace, Chicago Business Journal and Neuro News International.
Product and Technology
MIXED
MadSci's lead program is SmartShunt, an implantable hydrocephalus shunt system that integrates real-time intracranial pressure monitoring with adjustable valve technology, according to the Hydrocephalus Association and the company's portfolio profile at Catalytic Impact Foundation [PUBLIC] [Hydrocephalus Association] [Catalytic Impact Foundation]. The clinical premise is straightforward: hydrocephalus is managed by draining excess cerebrospinal fluid through an implanted shunt, but conventional shunts are essentially passive plumbing. They do not report whether they are over-draining, under-draining or occluded, and patients often present in the emergency department before a malfunction is recognized. SmartShunt is positioned as a connected device that surfaces ICP and flow data, in principle allowing earlier intervention and fewer revision surgeries [PUBLIC] [Isthmus Project].
The company describes itself on LinkedIn as "a fast-growing, early-stage medical device startup" developing "smart neuro devices" intended to "reimagine the future of hydrocephalus management" [PUBLIC] [LinkedIn]. The Org's company profile reiterates that MadSci is developing "a novel implantable hydrocephalus shunt system" [PUBLIC] [The Org]. Beyond these descriptions, technical specifications such as sensor architecture, telemetry protocol, battery and power approach, valve mechanism, and software stack are not publicly documented. No FDA clearance, CE mark, IDE status or published clinical data is currently in the public record [PUBLIC].
For underwriting purposes, the relevant unknowns are the regulatory pathway (a connected implantable with active electronics generally faces a more demanding review than a passive shunt), the manufacturing partner strategy, and whether the connected-device component will be marketed as part of the implant or as a separate cleared accessory. None of these have been disclosed [PUBLIC].
Data Accuracy: YELLOW -- Product concept confirmed by Hydrocephalus Association, Catalytic Impact Foundation and The Org; technical and regulatory specifics not publicly available.
Market Research and Opportunity
PUBLIC
Hydrocephalus is a small, stable, and chronically underserved category, which is precisely what makes a connected-device entrant interesting now. Three independent third-party reports converge on the basic shape of the market: it is sub-billion-dollar globally, it grows at a low single-digit CAGR, and it is dominated by long-tenured incumbents whose devices are largely mechanical.
Global Market Insights values the global hydrocephalus shunt market at $295.7 million in 2024 and projects a 3.5% CAGR through 2035 [Global Market Insights]. Grand View Research puts 2023 size at $456.1 million, projecting $599.4 million by 2030 at a 4% CAGR [Grand View Research]. Mordor Intelligence estimates 2025 size at $526.54 million growing to $616.35 million by 2030 at a 3.20% CAGR [Mordor Intelligence]. The variance between these figures reflects different definitions of in-scope products (valves only versus full system kits including catheters and accessories), but the directional picture is consistent.
| Source | Base Year | Base Size | Forecast Year | Forecast Size | CAGR |
|---|---|---|---|---|---|
| Global Market Insights | 2024 | $295.7M | 2035 | not stated | 3.5% |
| Grand View Research | 2023 | $456.1M | 2030 | $599.4M | 4.0% |
| Mordor Intelligence | 2025 | $526.5M | 2030 | $616.4M | 3.2% |
Analyst takeaway: the addressable shunt market is a niche by medtech standards, but it is a niche where unit economics can be attractive because procedure volumes are predictable, reimbursement codes are established, and the patient population (pediatric congenital hydrocephalus and adult normal-pressure hydrocephalus) is lifelong. A connected device that meaningfully reduces revision surgeries could command a price premium without needing to expand category volume.
The demand drivers cited across these reports are consistent: an aging population in developed markets that increases incidence of normal-pressure hydrocephalus, persistent pediatric demand, and growing interest in remote monitoring of implanted devices following the precedent set by cardiac rhythm management. The most relevant adjacent market is neuromodulation, where companies such as Medtronic and Abbott have built multi-billion-dollar franchises around implantable electronics with telemetry. Regulatory tailwinds include the FDA's continued willingness to grant Breakthrough Device designation to neuro-device entrants addressing inadequately served conditions, although MadSci has not publicly announced such a designation [PUBLIC].
Data Accuracy: GREEN -- Three independent market research firms cited (Global Market Insights, Grand View Research, Mordor Intelligence).
Competitive Landscape
MIXED
MadSci is entering a category whose installed base is controlled by a short list of long-tenured neurosurgical incumbents, against whom its bet is differentiation through data rather than displacement through price.
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| Madison Scientific (MadSci) | Connected implantable shunt with ICP monitoring | Seed, ~$10M disclosed | Real-time pressure data and adjustable valve in one system |
| Medtronic | Global incumbent in neurosurgical shunts (Strata, Delta) | Public (NYSE: MDT) | Largest installed base, full neuro portfolio |
| Integra LifeSciences | Programmable valve shunts (Certas Plus) | Public (NASDAQ: IART) | Strong neurosurgical sales channel |
| Aesculap (B. Braun) | proGAV / proSA programmable valves | Private subsidiary of B. Braun | European stronghold, gravitational valve design |
| Sophysa | Adjustable shunt valves (Polaris, Sophy) | Private (France) | Specialty pure-play, MRI-resistant valves |
| CereVasc | Endovascular CSF shunt (eShunt) | Venture-backed | Minimally invasive alternative to traditional shunting |
The segment splits cleanly into three groups. The incumbents (Medtronic, Integra, Aesculap, Sophysa) compete on programmable valve sophistication and surgeon relationships, their products are mechanical and pressure-adjustable transcutaneously, but none of the four publicly market a fully connected, telemetry-enabled implant in this category as of the most recent public disclosures [PUBLIC]. The challenger group is led by CereVasc, whose eShunt approaches the same clinical problem from a fundamentally different angle (endovascular delivery rather than surgical implantation), which makes it less a head-on rival than an alternative therapeutic modality that could ultimately compete for the same patient. MadSci occupies a third position: a connected, sensor-bearing version of the conventional shunt form factor, which is the product physicians already know how to implant.
MadSci's defensible edge today, if the device performs as described, is data. A shunt that produces a continuous ICP record creates a clinical artifact that incumbents do not, and that artifact has compounding value: it informs valve adjustments, it shortens diagnostic workups when patients present with symptoms, and over time it becomes a dataset for refining when and how to intervene. That edge is durable to the extent that incumbents would need to re-architect their devices and re-clear them with regulators to match it, which is a multi-year undertaking. It is perishable to the extent that an incumbent with deeper pockets could acquire a competing sensor program or partner with a neuromonitoring company to leapfrog.
MadSci is most exposed on three fronts. First, distribution: Medtronic and Integra have decades-old relationships with neurosurgery departments, and a seed-stage company will need either a strategic partner or a patient direct sales build to reach implanting surgeons at scale. Second, regulatory timeline: a connected active implantable typically faces a more demanding pathway than a passive valve revision, and any clinical hold or design iteration extends runway risk. Third, an alternative-modality risk from CereVasc: if endovascular CSF diversion proves durable in larger studies, a portion of the addressable patient population may shift away from conventional shunting altogether.
The most plausible 18-month competitive scenario: MadSci wins if it can publish credible early human data showing that its monitoring meaningfully reduces revision rates or hospital readmissions, which would make the company an attractive partnership or acquisition target for one of the incumbents named above. MadSci loses ground if a competitor (most plausibly Integra, given its programmable valve franchise) announces a connected upgrade to an already-cleared platform, collapsing MadSci's first-mover differentiation before its own device reaches commercial use.
Data Accuracy: YELLOW -- Subject company facts from Crunchbase and Neuro News International; competitor positioning based on public company descriptions and category knowledge, not on a head-to-head independent benchmark.
Opportunity
PUBLIC
If MadSci becomes the first connected shunt to reach broad commercial use, it would not just take share in a $300M-$600M category, it would arguably redefine what a hydrocephalus shunt is.
The headline opportunity. The single largest outcome for MadSci is to become the default architecture for hydrocephalus shunting in developed markets, replacing passive mechanical valves with sensor-enabled implants the way drug-eluting stents displaced bare-metal stents in interventional cardiology. The cited evidence makes this reachable rather than aspirational because the category is small enough that a single differentiated entrant can move the standard of care without needing to win on price, and because incumbents have not publicly fielded a connected competitor [Global Market Insights] [Mordor Intelligence]. The clinical pull is real: shunt failure and revision rates in hydrocephalus are well-documented in the neurosurgical literature, which is the underlying reason mission-aligned backers such as Catalytic Impact Foundation have explicitly framed MadSci as "redefining the standard of care" [Catalytic Impact Foundation].
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Standard-of-care capture | SmartShunt becomes the preferred first-line implant at major pediatric and academic neurosurgery centers | Published clinical data showing reduced revision rate, followed by inclusion in society guidelines | Hydrocephalus is a chronic, lifelong condition with high revision burden; the market is small enough for a single differentiated device to set the new norm [Mordor Intelligence] |
| Strategic acquisition by a neurosurgical incumbent | Medtronic, Integra or Aesculap acquires MadSci to add a connected device to an existing valve portfolio | Successful first-in-human results plus FDA clearance | Incumbents already own programmable valve franchises but no connected implant; bolt-on M&A is the established path to add new modalities in neurosurgery [PUBLIC] |
| Platform expansion into adjacent CSF and ICP indications | The same sensor and telemetry stack is repurposed for traumatic brain injury monitoring, idiopathic intracranial hypertension, or post-surgical drainage | A second clinical indication enters preclinical or pilot work | The underlying technology (intracranial pressure sensing plus an adjustable flow path) is broadly applicable across CSF disorders [Hydrocephalus Association] |
What compounding looks like. The flywheel for a connected implant is data, and the data flywheel in hydrocephalus is unusual because patients carry the device for life. Each implant produces a longitudinal ICP record that, in aggregate, creates a clinical dataset no incumbent owns. That dataset informs three downstream advantages: better valve-adjustment algorithms (which improve outcomes and reinforce surgeon preference), shorter diagnostic workups when patients present at the ED (which reduces total cost of care and creates a payer story), and a regulatory moat as future entrants must match not only the device but the evidence base behind it. There is no public evidence yet that this flywheel is turning, since the device is pre-commercial, but the architecture is set up to support it.
The size of the win. The hydrocephalus shunt category sits between roughly $296M and $526M globally today depending on the report [Global Market Insights] [Mordor Intelligence]. Comparable connected-implant categories are materially larger: the global cardiac rhythm management market, the closest precedent for telemetry-enabled implants, is measured in the tens of billions. A more proximate comparable is the acquisition multiples paid for differentiated neurosurgical device companies by strategics like Medtronic and Integra, which historically have ranged into the high hundreds of millions for pre-revenue or early-revenue assets with strong clinical data. If the standard-of-care capture scenario plays out, a credible exit valuation in that range is conceivable (scenario, not a forecast). If the platform-expansion scenario also plays out, the comparable set shifts toward neuromodulation, where outcomes have historically been larger still (scenario, not a forecast).
Data Accuracy: YELLOW -- Market sizing and category structure confirmed by named third-party reports; scenario translation is analyst interpretation explicitly labelled as such.
Sources
PUBLIC
[Crunchbase] Madison Scientific - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/madison-scientific
[Crunchbase, March 2025] Seed Round - Madison Scientific - 2025-03-18 | https://www.crunchbase.com/funding_round/madison-scientific-seed--8c724d96
[Crunchbase, September 2025] Seed Round - Madison Scientific - 2025-09-08 | https://www.crunchbase.com/funding_round/madison-scientific-seed--c001b3ad
[Crunchbase] Tyler Wanke - Founder, CEO and Board Member, Madison Scientific | https://www.crunchbase.com/person/tyler-wanke
[PitchBook] Madison Scientific 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/466913-44
[LinkedIn] Madison Scientific Inc on LinkedIn | https://www.linkedin.com/company/madison-scientific-inc
[The Org] Madison Scientific Inc company profile | https://theorg.com/org/madison-scientific-inc
[Impact Foundation] Madison Scientific portfolio page | https://www.impactfoundation.org/portfolio/madisonscientific
[Catalytic Impact Foundation] Madison Scientific - SmartShunt Innovation in Hydrocephalus Management | https://www.cifimpact.org/madsci
[Neuro News International] MadSci announces US$10 million seed financing to advance SmartShunt hydrocephalus treatment | https://neuronewsinternational.com/madsci-announces-us10-million-seed-financing-to-advance-smartshunt-hydrocephalus-treatment/
[MobiHealthNews] MadSci raises $10M in seed funding for hydrocephalus system | https://www.mobihealthnews.com/news/madsci-raises-10m-seed-funding-hydrocephalus-system
[BioSpace] Madison Scientific Closes $7M in Seed Financing | https://www.biospace.com/press-releases/madison-scientific-closes-7m-in-seed-financing
[Chicago Business Journal] Northwestern professor's SmartShunt device startup gets $7M in seed funding | https://www.chicagobusiness.com/health-pulse/madison-scientific-raises-7m-seed-funding
[Isthmus Project] Building a smarter shunt for hydrocephalus patients | https://www.isthmusproject.com/story/building-a-smarter-shunt-for-hydrocephalus-patients
[Hydrocephalus Association] Coverage of MadSci SmartShunt program
[Northwestern University Farley Center] Profile of Tyler Wanke
[Global Market Insights] Hydrocephalus Shunt Market report (2024 base year)
[Grand View Research] Hydrocephalus Shunts Market Size Report (2023 base year)
[Mordor Intelligence] Hydrocephalus Shunts Market Size & Share Analysis (2025 base year)
Articles about Madison Scientific Inc.
- Madison Scientific Is Building a Smarter Brain Shunt for Hydrocephalus Patients — The Chicago startup closed $10M in seed funding to bring real-time pressure sensing to a device class that has changed little in decades.